Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 25.7 USD -0.27%
Market Cap: 145.6B USD
Have any thoughts about
Pfizer Inc?
Write Note

Pfizer Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pfizer Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Change in Working Capital
$378m
CAGR 3-Years
-70%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Change in Working Capital
$4.3B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Change in Working Capital
$389m
CAGR 3-Years
N/A
CAGR 5-Years
-27%
CAGR 10-Years
-7%
Merck & Co Inc
NYSE:MRK
Change in Working Capital
-$1.7B
CAGR 3-Years
17%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zoetis Inc
NYSE:ZTS
Change in Working Capital
-$28m
CAGR 3-Years
50%
CAGR 5-Years
28%
CAGR 10-Years
21%
Eli Lilly and Co
NYSE:LLY
Change in Working Capital
-$6.3B
CAGR 3-Years
-81%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
No Stocks Found

Pfizer Inc
Glance View

Market Cap
145.6B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Pfizer Inc. is a global leader in the pharmaceutical industry, renowned for its commitment to innovative research and development that drives breakthroughs in healthcare. Founded in 1849, Pfizer has evolved into a powerhouse, particularly highlighted by its pivotal role in developing one of the first COVID-19 vaccines in collaboration with BioNTech. This achievement not only underscored the company's rapid response capabilities but also significantly boosted its revenue, showcasing its ability to pivot in times of global health crises. Investors are drawn to Pfizer not just for its historical legacy, but also for its diverse portfolio that includes treatments across various therapeutic areas such as oncology, immunology, and neurology, reflecting a balanced strategy poised for future growth. As Pfizer continues to navigate a post-pandemic world, its focus on innovation remains a cornerstone of its business strategy. With a robust pipeline of drugs in late-stage development and a strong commitment to mergers and acquisitions, Pfizer is determined to maintain market leadership while expanding its therapeutic offerings. Importantly, the company is also committed to shareholder value, consistently returning profits through dividends and share buybacks. For investors, Pfizer represents a compelling opportunity, merging stability with the potential for growth in an ever-evolving healthcare landscape, driven by advancements in science and technology.

PFE Intrinsic Value
24.41 USD
Overvaluation 5%
Intrinsic Value
Price

See Also

What is Pfizer Inc's Change in Working Capital?
Change in Working Capital
378m USD

Based on the financial report for Sep 29, 2024, Pfizer Inc's Change in Working Capital amounts to 378m USD.

What is Pfizer Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
-70%

The average annual Change in Working Capital growth rates for Pfizer Inc have been -70% over the past three years .

Back to Top